MYOGENICA INC.

Saint Paul, MN · Founded 2021 · Biotech · Private

Cell therapy treatment for Duchenne muscular dystrophy using engineered muscle cells to restore dystrophin production

Claim this profile

Follows are private to you and power your alerts

Updated · myogenica.com

Sector
Biotech
Headquarters
Saint Paul, MN
Founded
2021
Latest Form D
$100K, Mar 2022
Total capital
$1.7M
Federal grants
$1.6M
2 awards · 2023–2025
Rank in peer group#482 of 514
Private capital raised
$100K
1 Form D · last Mar 2022
55 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
None on recordNo USPTO grants. Applications publish after 18 months.

Capital timeline

2022202320242025FEDERAL ↑EQUITY ↓Cumulative $1.7M$293K$1.3M1st Form D$100K
2022202320242025FEDERAL ↑EQUITY ↓Cumulative $1.7M$293K$1.3M1st Form D$100K

Latest events

  • Federal grantHealth and Human S · Phase II · Systemic Transplantation of MyoPAXon: IND Enabling Studies for the Treatment of DMD$1.3M
  • Federal grantHealth and Human S · Phase II · Systemic Transplantation of MyoPAXon: IND Enabling Studies for the Treatment of DMD$293K
  • Private capital raisedForm D · SEC · 1st filing$100K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 514 peers

Line = median

Biotech · Molecule

  • Federal grantsBelow median

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants
  • Michael Allen KybaResearcherDirectorLinked by $1.6M in grants as PI
  • Paul Allen HawkinsExecutive Officer, DirectorNamed in SEC Form D filings
  • Rita Allen PerlingeiroDirectorNamed in SEC Form D filings

What it has protected

No granted patents are on record.

USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.

Checked: USPTO granted patents and published applications · Oct 23, 2026

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .